Why Some Patients Never Reach Second Line Therapy in Advanced RCC

Here the panel addresses a sobering clinical reality: not all patients with advanced RCC reach second or subsequent lines of therapy. Despite multiple approved options, attrition between lines remains significant.

Clinicians describe patients with aggressive biology, rapidly progressive liver involvement, symptomatic brain metastases, or declining performance status who deteriorate quickly. In some cases, disease progresses despite appropriate frontline therapy, limiting the opportunity to transition to another regimen. Hyperprogression and primary resistance to immune checkpoint inhibitors are acknowledged as poorly understood but clinically impactful patterns.

The discussion broadens to the implications for initial therapy selection. If a meaningful proportion of patients may never receive second line therapy, then achieving meaningful disease control early becomes critical. The panel references ongoing research efforts aimed at identifying resistance sooner, including trials exploring circulating biomarkers such as KIM-1 and other blood based approaches to detect inadequate response before overt clinical decline.

The group also mentions emerging investigational strategies, including microbiome related research and other biologically driven trials, aimed at improving early disease control.

The key takeaway is that sequencing decisions must account for the possibility that later lines may never be realized. Frontline therapy selection carries significant weight in this context.